India’s pharmaceutical sector is heading into a mixed March quarter, with drugmakers head into uneven Q4 as margins come under strain from US pricing pressure, loss of high-margin opportunities, and rising costs.
India’s Revised Safety Norms are set to change how hospitals grow, with the Centre easing long-standing restrictions on building height. The Bureau of Indian Standards (BIS) has removed the 45-metre cap on hospital structures under the newly...
The Centre has relaxed CME rules, medtech firms, and UCMPMD code requirements, making it easier for companies to organise training and educational programmes for healthcare professionals. The revised policy aims to reduce approval delays whil...
Indegene Q4 FY26 revenue crossed a major milestone, but profits told a different story. The company reported revenue of Rs 1,003 crore for the quarter, marking a strong 32.8 percent year-on-year growth and its first time breaching the...
Dr. Reddy's Laboratories has secured a key regulatory win as its semaglutide injection receives approval from Health Canada, marking a major step in the global rollout of lower-cost alternatives to blockbuster diabetes and weight-loss drugs.
India’s pharma sector funding, investment, mergers, and acquisitions activity during April 20–26 highlights a week shaped by mega M&A deals, strategic investments, and capital allocation moves. From Sun Pharma’s global acquisition to AI-driven...
Gujarat Themis Biosyn Limited (GTBL) has announced a major step in its global expansion with the signing of an agreement to acquire a portfolio of anti-tuberculosis and anti-infective brands from Sanofi. The GTBL acquisition of Sanofi TB...
India and Brazil on Saturday signed a India-Brazil MoU to strengthen cooperation in regulating pharmaceutical and medical products, marking a key move to deepen health sector ties. The agreement was formalized at Hyderabad House between Central...
Supriya Lifescience Limited has received a major regulatory boost as the U.S. Food and Drug Administration issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification for its API manufacturing unit in...
India’s CDSCO prior intimation mechanism is now live, marking a shift in how drug makers begin early-stage manufacturing for research. The Central Drugs Standard Control Organisation has rolled out the system from April 21, 2026, replacing the...
, CDSCO.jpg)